Synopsis The current treatment guidelines for psoriatic arthritis (PsA) recommend conventional synthetic disease-modifying antirheumatic drugs (DMARDs) followed by biologic DMARDs or apremilast. The present study aims to evaluate the safety and efficacy of tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic DMARDs. This week’s “MED FACT” discusses a clinical study from The New England Journal of Medicine, “ Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis ”. Aug 2018. Authors : P.
Mease; S. Hall O. FitzGerald; et al. Key Takeaways: Tofacitinib provides an alternative mechanism of action, as compared with current treatment options for psoriatic arthritis. Objective: To evaluate the safety and efficacy tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response…
